Sanofi SA
46 Avenue De La Grande Armée, Paris, IDF 75017
Related Posts:
Sanofi’s Cenrifki recommended for EU approval to treat secondary progressive multiple sclerosis
April 24, 2026
Sanofi announced that its drug Cenrifki has been recommended by European regulators for treating certain forms of multiple sclerosis. The recommendation follows positive results from clinical trials showing delayed disability progression. A final regulatory decision is expected soon.
Read more →Sanofi announces successful pricing of €2.3 billion bond issue in three tranches
April 24, 2026
Sanofi has successfully priced a €2.3 billion bond issue across three tranches with varying maturities. The proceeds will support general corporate purposes as part of its ongoing financial strategy.
Read more →Sanofi reports double-digit sales and EPS growth in first quarter of 2026
April 23, 2026
Sanofi reported strong financial results for Q1 2026 with double-digit increases in both net sales and earnings per share at constant exchange rates. The company highlighted robust pharmaceutical launches, solid performance from Dupixent, ongoing R&D investment, pipeline progress, major acquisitions completed during the period—and confirmed its outlook for further profitable growth this year.
Read more →Sanofi’s Tzield receives FDA approval to delay type 1 diabetes in young children
April 22, 2026
Sanofi announced FDA approval expanding Tzield’s use to delay advanced type 1 diabetes onset in children as young as one year old. Experts say this could significantly help families manage early-stage disease progression.
Read more →Sanofi announces FDA extends review of Sarclisa subcutaneous application in the US
April 22, 2026
Sanofi announced that US regulators have extended their review period for Sarclisa subcutaneous until July. If approved, it could become the first anticancer drug delivered via an on-body injector.
Read more →Sanofi reports Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in study
April 18, 2026
Sanofi announced new data showing its protein-based COVID-19 vaccine Nuvaxovid had fewer side effects compared to Moderna's latest mRNA vaccine in a recent clinical trial involving U.S. adults. Researchers say these findings could help improve public confidence and increase future vaccination rates.
Read more →Sanofi reports lunsekimig met key endpoints in phase 2 asthma and CRSwNP studies
April 7, 2026
Sanofi announced positive results from phase 2 studies of its drug candidate lunsekimig in moderate-to-severe asthma and chronic rhinosinusitis with nasal polyps. The company reported that key efficacy endpoints were met while maintaining an acceptable safety profile. Further research is ongoing as detailed trial data will be shared at future medical meetings.
Read more →Sanofi’s Rezurock receives EU approval for chronic graft-versus-host disease treatment
March 31, 2026
Sanofi announced that Rezurock has received conditional marketing authorisation from the European Commission for treating chronic graft-versus-host disease in adults and adolescents aged twelve years or older when other treatments are not suitable or effective. The decision follows positive clinical trial results showing meaningful responses among heavily pretreated patients.
Read more →Sanofi presents phase 3 amlitelimab study results in atopic dermatitis at AAD meeting
March 28, 2026
Sanofi has presented new phase 3 trial results showing its experimental drug amlitelimab improved outcomes for people with moderate-to-severe atopic dermatitis. The findings were shared during a major dermatology conference in Denver. Experts say there is still an unmet need for new treatments.
Read more →
Trending
The Weekly Newsletter
Sign-up for the Weekly Newsletter from EU Business Daily.